Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

被引：40

作者：

Assi, Tarek ^{[1
]}

Kattan, Joseph ^{[1
]}

Rassy, Elie ^{[1
,2
]}

Nassereddine, Hussein ^{[1
]}

Farhat, Fadi ^{[1
]}

Honore, Charles ^{[2
]}

Le Cesne, Axel ^{[2
]}

Adam, Julien ^{[2
]}

Mir, Olivier ^{[2
]}

机构：

[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, Beirut, Lebanon

[2] French Sarcoma Grp, Gustave Roussy Canc Campus, Villejuif, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷

关键词：

Liposarcoma; Soft tissue sarcoma; CDK4; MDM2; Palbociclib; Abemaciclib; Ribociclib; SOFT-TISSUE SARCOMA; PHASE-II; 1ST-LINE TREATMENT; SYNOVIAL SARCOMA; INHIBITOR; CANCER; DOXORUBICIN; ABEMACICLIB; PALBOCICLIB; EFFICACY;

D O I：

10.1016/j.critrevonc.2020.103029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

引用

下载

页数：6

共 50 条

[1] Amplification of the cyclin-dependent kinase 4 (CDK4) gene and CDK4 overexpression in a subgroup of pancreatic carcinomas
Bartsch, D
Barth, P
Arnold, R
Simon, B
GASTROENTEROLOGY, 1999, 116 (04) : A1164 - A1164
[2] Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme
Rollbrocker, B
Waha, A
Louis, DN
Wiestler, OD
vonDeimling, A
ACTA NEUROPATHOLOGICA, 1996, 92 (01) : 70 - 74
[3] Impact of Cyclin-Dependent Kinase CDK4 Inhibition on Eryptosis
Lang, Elisabeth
Zelenak, Christine
Eberhard, Matthias
Bissinger, Rosi
Rotte, Anand
Ghashghaeinia, Mehrdad
Lupescu, Adrian
Lang, Florian
Qadri, Syed M.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2015, 37 (03) : 1178 - 1186
[4] Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors
Koehler, Lena
Graf, Franziska
Bergmann, Ralf
Steinbach, Joerg
Pietzsch, Jens
Wuest, Frank
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (02) : 727 - 737
[5] Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma
Zhou, Yubing
Shen, Jacson K.
Yu, Zujiang
Hornicek, Francis J.
Kan, Quancheng
Duan, Zhenfeng
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (05): : 1573 - 1582
[6] Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors
Lindberg, Daniel
Hessman, Ola
Akerstroem, Goeran
Westin, Gunnar
NEUROENDOCRINOLOGY, 2007, 86 (02) : 112 - 118
[7] Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product
Soni, R
Muller, L
Furet, P
Schoepfer, J
Stephan, C
Zumstein-Mecker, S
Fretz, H
Chaudhuri, B
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 275 (03) : 877 - 884
[8] Novel cyclin-dependent kinase 4 (Cdk4) inhibitors as potential anticancer agents.
Joshi, KS
Rathos, M
Mahajan, P
Wagh, V
Shenoy, S
Lai, B
Mascarenhas, M
Kamble, S
Kulkarni, S
Totre, J
CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6222S - 6222S
[9] EXPRESSION OF THE CYCLIN-DEPENDENT KINASE CDK4 IN PERINATAL AND ADULT-RAT LUNG
BRESLIN, JS
PHILLIPS, KS
WEAVER, TE
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1993, 9 (05) : 533 - 540
[10] CHARACTERIZATION OF THE TEMPORAL AND SPATIAL EXPRESSION OF CDK4 (CYCLIN-DEPENDENT KINASE) IN RAT LUNG
BRESLIN, JS
CHO, FS
PHILLIPS, KS
WEAVER, TE
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (04): : A498 - A498

← 1 2 3 4 5 →